If the relationship of DNMT3a mutations with increased cardiovascular risk in CKD patients is confirmed in larger studies, it could suggest the existence of new specific mechanisms for the progression of the disease, atherosclerosis in patients with nephropathies, and new therapeutic alternatives. This evidence concerns the gene DNMT3A and Nephropathy.